Overall, these data support ErbB2 as a client protein of HSP90 and indicate that the selective targeting of ErbB2 is a critical component of the anti-cancer mechanism of ganetespib in ErbB2+ breast cancer cells. Here, ERBB2 is linked to breast carcinoma.